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Tilman Sauerbruch⇑
Medical Faculty, University of Bonn, GermanyCelui qui cherche la vraie science doit la pêcher là où elle se
trouve
Michel de Montaigne 1533–1592
The ﬁrst time I heard of Didier Lebrec was in 1981 after an
article had appeared in the New England Journal of Medicine enti-
tled ‘‘Propranolol for prevention of recurrent gastrointestinal
bleeding in patients with cirrhosis: a controlled study’’ [1]. At
that time, I was working in Gustav Paumgartner’s group at the
University of Munich. We were planning to perform a study to
test sclerotherapy for the prophylaxis of ﬁrst variceal bleeding
in patients with large esophageal varices [2]. With this new and
provocative paper in mind, we discussed whether we should
treat the conservative arm with propranolol.
There was a meeting on cirrhosis and its complications in Lon-
don. Jean Pierre Benhamou was one of the chairmen and Didier
Lebrec one of the speakers. Gustav told me to contact Benhamou
to get more information on the value of non-selective b-blockers
(NSBB) for the treatment of portal hypertension. I met Didier Leb-
rec in the hotel lobby and asked to meet Jean Pierre Benhamou.
When I told him what I wanted he said: ‘‘You should ask me, I
am the one who performed the study’’. We decided against pro-
pranolol in the second arm. It was difﬁcult for us to accept the
rationale of treating these patients with an NSBB. We were afraid
that the hemodynamic reaction would be impaired in case of
bleeding, the kidney function would deteriorate, etc. Later on, a
second study performed by Andrew Burroughs at the Royal Free
Hospital in London was published [3]. The authors found no dif-
ference in rebleeding after esophageal hemorrhage between the
control and propranolol groups, so we were happy about our
decision. But today, it is clear that we were wrong. Three decades
after the ﬁrst report that oral treatment with NSBB decreases por-
tal pressure, these drugs are still the treatment of choice for the
prophylaxis of ﬁrst variceal bleeding and rebleeding, together
with the ligation of varices. The conclusions of the prestigious
Baveno consensus meetings, where Roberto de Franchis gathered
experts in portal hypertension, have continuously conﬁrmed this
[4]. Although the participants have aged, NSBB are as topical as
ever. What other indication for a drug has remained unchanged
for 30 years? Very few! The treatment of portal hypertension isJournal of Hepatology 20
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clinical practice to span decades.
The story behind this achievement is closely connected to an
assumption made by a young French hepatologist at Hôpital
Beaujon in Clichy, Paris. When he read a paper showing the portal
pressure reducing effect of somatostatin, Didier hypothesized
that splanchnic hyperperfusion might be present in patients with
cirrhosis, increasing portal hypertension by an increase in portal
tributary blood ﬂow. Didier thought that this dynamic compo-
nent might respond to drugs that decrease the portal tributary
blood ﬂow. He chose an NSBB [5], which reduces cardiac output
on the one hand, while possibly causing an unopposed splanchnic
alpha-adrenergic reaction on the other hand. As a result of work-
ing from 1973 to 1974 as a Fulbright postdoc with the cardiolo-
gist Jay N. Cohn at Georgetown University, Washington DC,
Didier had learned about the importance of the systemic circula-
tion. Furthermore, early in his career, he had learned to measure
the hepatic venous pressure gradient (HVPG), which reﬂects por-
tal pressure [6]. He was also the ﬁrst hepatologist in Europe to
perform transvenous (transjugular) liver biopsies [7,8]. With
these skills and this expertise, it was easy for Didier to measure
HVPG in the portal vein in humans and to conﬁrm his hypothesis.
His group performed an elegant study showing that continuous
administration of propranolol leads to a sustained reduction in
the HVPG and heart index without affecting hepatic blood ﬂow
[9]. Later, they used animal models of cirrhosis using micro-
spheres to prove that during portal hypertension, splanchnic
blood ﬂow is indeed increased while the hepatic blood ﬂow,
which is a fraction of splanchnic blood ﬂow, is not [10]. Thus,13 vol. 59 j 405–407
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Didier Lebrec and Roberto Groszmann [11] identiﬁed an impor-
tant paradox in the pathophysiology of portal hypertension and
cirrhosis: namely that while vasoconstriction is present in the
liver, vasodilatation is observed in the splanchnic and systemic
vascular system.
Over time, numerous clinical trials published in the most
prestigious journals [12,13] have proven that Didier’s treatment
of portal hypertension with non-selective b-blockers was correct.
Today, new ﬁndings are often generated by mass screening
techniques that can generate new ﬁndings and associations that
may be of great clinical importance. This is possible thanks to
the revolution in biostatistics and may become the subject of fur-
ther research on function [14,15]. Didier’s approach, however,
was completely the opposite. His hypothesis was based on an
educated guess. He then worked to prove the hypothesis by per-
forming hemodynamic measurements and controlled clinical tri-
als, one at a time. Few scientists are competent and lucky enough
to identify a new treatment that is accepted worldwide and used
for decades.
During his nearly 40 years at Hôpital Beaujon in Paris, where
he was also Director of Research at the National Institute of
Health (INSERM), Didier Lebrec trained 34 fellows from France
and 28 from other countries in Europe, America, and Asia. Two
of these were members of my group. They came back with new
ideas, new methods, and wonderful memories for the rest of their
lives of this large family where clinical research and ‘‘savoir vivre’’
were shared in Paris. Together with these young co-workers and
the members of the Liver Unit in Clichy (Richard Moreau and so
many others), the group made an enormous contribution to our
knowledge on portal hypertension, especially on the endogenous
factors involved in the control of arterial tone in cirrhosis [16,17].
Even today, we do not fully understand why there is an impaired
response to vasoconstrictors in the dilated vessels [18]. Didier
and his group have shown that NOS upregulation [19], partly
due to bacterial translocation [20] may be one reason. Last but
not least, the group showed that there is a signiﬁcantly aug-
mented inﬂammatory response to LPS in cirrhosis as compared
to controls [21]. This was the basis of Didier’s last large
randomized controlled study – which was again hypothesis dri-
ven – namely by treating cirrhosis with the anti-TNF molecule,
pentoxifylline [22].
Didier Lebrec was not only involved in research in hepatology,
he also looked after his patients, postdocs at Hopital Beaujon, and
the community of hepatologists worldwide. He was a scientiﬁc
committee member and president of the French Association for
the Study of the Liver, scientiﬁc committee member of the Euro-
pean Association for the Study of the Liver (EASL) and president
of the International Association for the Study of the Liver (IASL).
He has been in the editorial boards of all the highly ranked inter-
national journals in the ﬁeld of liver disease and he was associate
editor of the Journal of Hepatology. Today, he is still the editor in
chief of the European Journal of Gastroenterology and Hepatology.
What qualities are needed for such a career? There are no
standard answers, but the most important are ideas, a passionate
interest and a structured approach, as well as a sincere and unbi-
ased attitude when analyzing raw data, self-conﬁdence, and a
good team.
When I visited Didier in March 2013, he was still working in
his ofﬁce on the ﬁrst ﬂoor of the Pavillon Abrami, Hopital Beau-
jon, surrounded by photos of friends he had met at the many
research meetings he had attended around the world, and by406 Journal of Hepatology 201walls of books, journals, and papers. Didier has followed his
path over a period of four decades, and a visit to his ofﬁce is a
proof of this: a living, active, working space allowing creative
scientiﬁc thoughts based on the solid foundations of scientiﬁc
exchange and the highest level literature from worldwide
experts.
Didier Lebrec was born in Paris as the third of six children. His
father was a member of the famous Ecole Polytechnique, one of
the grandes écoles in France. In the French tradition, Didier was
sent to the prestigious Lycée Louis-le-Grand. Fortunately for
hepatology, Didier did not become a polytechnicien, but began
studying medicine, met his mentor, Jean Pierre Benhamou, and
started his 40-year journey.
He is the father of two sons and one daughter and the grand-
father of ﬁve grandchildren. All the members of his large family
live in Paris and the close banlieu, enjoying life in this cultural
centre of Europe. But Didier also has close connections with the
New World, he has been happily married for 20 years to his wife,
Dale, who has her roots on the East Coast of the US.
When I visited Didier, he showed me a photo of the garden
that he and Dale had created in their country house in the Perche,
near Chartres. Today he spends more and more time there,
studying the different plants, trees and bushes, looking at other
gardens in the area, then adapting the garden, choosing
plants that will thrive in the local terrain, just as he has done
throughout his career in the ﬁeld of hepatology and portal
hypertension.References
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